Canary Capital is pleased to provide an updated research report on Biome Australia Limited (ASX:BIO).
A link to the new report is provided below. In this comprehensive update we have added 2029 to our forecasts, and also adjusted the company-specific risk premium down by 0.5% to 2.5%. This is because the company has consistently beat forecasts and has been cash flow positive for the last three quarters.
The discounted cash flow valuation for the company has increased to $1.10 per share from $0.79.
In this report we have also included more information about the new Biome Cholesterol product as well as updated the barriers to entry for competitors and provided new examples of actual pharmacy store sales growth in mainland Australia.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)